Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer
Cabozantinib and sunitinib are both drugs that block the development [...]
Biomarkers for avelumab plus axitinib in advanced kidney cancer
The discovery of a reliable biomarker for how patients with [...]
ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer
Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
First-line treatment of kidney cancer
These two videos with Dr Eric Jonasch from MD Anderson [...]
Advances in systemic treatments for metastatic kidney cancer
In this video interview Professor Jens Bedke from the Department [...]
Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer
In this retrospective study published in Cancer Reports the association [...]
Safety and efficacy of apatinib for metastatic kidney cancer
A recent study coming out of China has identified a [...]
